Odyssey Therapeutics ODTX

NASDAQ ODTX

$19.30 -0.30 (-1.53%)

At close: Oct 26, 2026 · 4:00 PM EDT

Odyssey Therapeutics (ODTX) stock price is $19.30, down 1.53% on the day, as of Oct 26, 2026. It is classified in the Pharmaceuticals industry (Healthcare sector).

Key Stats

Add ratio to table…

About

Odyssey Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing transformative medicines for autoimmune and inflammatory diseases by targeting key signaling nodes in the innate immune system. The company draws on expertise in immunobiology medicinal and computational chemistry protein biochemistry structural biology genetics and pharmacology to identify and modulate disease relevant proteins such as RIPK2 and SLC15A4. Its lead programs include OD-001 an oral small molecule RIPK2 scaffolding inhibitor in phase 2a development for ulcerative colitis and OD-002 an oral small molecule SLC15A4 inhibitor in IND enabling studies for interferonopathies.

As a clinical stage company Odyssey Therapeutics, Inc. has not yet generated product revenue and relies on financing from investors and collaboration agreements to fund its operations. Since its inception in 2021 the company has raised approximately $726.5 million from over 30 venture capital investors mutual funds long only funds global family offices and corporate venture funds. The company also has a collaboration with Terray Therapeutics to develop an IRF5 inhibitor.

Odyssey Therapeutics, Inc. positions itself as an innovator in innate immune modulation a field where many competitors focus on adaptive immune pathways. Several companies are developing RIPK2 inhibitors while others pursue SLC15A4 TNFR2 TSLP and IL 33 IRAK4 and IRF5 targets. The company's advantages include a deep understanding of immunobiology a proprietary AI/ML platform for small molecule discovery and expertise in both small molecule and protein therapeutic modalities. Its experienced leadership team has a track record of building successful biopharmaceutical companies and advancing drug candidates into clinical trials.

Odyssey Therapeutics, Inc. collaborates with Terray Therapeutics on its IRF5 inhibitor program. The company works with the clinical research organization Alimentiv to conduct its clinical trials. Ultimately the company intends to serve patients with autoimmune and inflammatory diseases as well as healthcare providers and payors that will use its approved therapies.

Investment Thesis

▲ Bull case

Odyssey Therapeutics is advancing a clinical-stage biopharmaceutical company with a portfolio of internally discovered and developed medicines targeting autoimmune and inflammatory diseases, which represents a significant unmet medical need with large addressable markets, and the company has already achieved multiple clinical milestones for its lead programs in just over two years since founding in 2021, demonstrating rapid preclinical-to-clinical translation efficiency that suggests a robust discovery engine and de-risked near-term value inflection points as data readouts approach, positioning the company to capture early-mover advantage in precision immunology where current therapies often lack durability or specificity or broad immunosuppression.
The recent appointment of Jolie M. Siegel as Executive Vice President, General Counsel brings over two decades of specialized biotechnology legal and transactional experience, including guiding C4 Therapeutics through significant growth and Neon Therapeutics through its acquisition by BioNTech, indicating strengthened capacity to navigate complex intellectual property landscapes, secure favorable partnership or licensing deals, and manage regulatory and compliance risks as the company advances its pipeline, which is critical for a clinical-stage biotech preparing for potential inflection events such as Phase 2 data readouts or strategic transactions that could unlock non-dilutive funding or validate platform value.
The addition of H. Martin Seidel, Ph.D., to the Scientific Advisory Board provides deep expertise in drug discovery, translational science, and portfolio strategy from leadership roles at Novartis and IFM Therapeutics, where he oversaw multiple successful portfolio company exits, suggesting enhanced ability to prioritize high-potential targets, optimize clinical development paths, and make informed go/no-go decisions that increase the probability of clinical success and efficient capital allocation, directly addressing a key investor concern in early-stage biotech: whether the science can reliably translate into viable clinical candidates.
Odyssey’s focus on developing medicines designed to precisely target disease pathology—rather than broad immune suppression—aligns with a growing structural shift in immunology toward precision medicine, where next-generation therapies aim for deep and durable remission with improved safety profiles, and if successful, this approach could differentiate the company’s pipeline in crowded markets like inflammatory bowel disease or rheumatoid arthritis, where current standards of care often lose efficacy over time or carry significant side effects, creating a potential long-term commercial advantage if clinical validation follows.
The company’s emphasis on internal discovery and development, coupled with a comprehensive suite of tools to efficiently advance product candidates, indicates a scalable and capital-efficient R&D model that reduces reliance on external innovation and lowers attrition risk through better target validation, which, if sustained, could lead to a higher hit rate in clinical development compared to peers and support a durable pipeline capable of generating multiple near-term catalysts, a factor often underestimated by the market when valuing early-stage immunology companies solely on near-term cash burn.

Odyssey Therapeutics is advancing a clinical-stage biopharmaceutical company with a portfolio of internally discovered and developed medicines targeting autoimmune and inflammatory diseases, which represents a significant unmet medical need with large addressable markets, and the company has already achieved multiple clinical milestones for its lead programs in just over two years since founding in 2021, demonstrating rapid preclinical-to-clinical translation efficiency that suggests a robust discovery engine and de-risked near-term value inflection points as data readouts approach, positioning the company to capture early-mover advantage in precision immunology where current therapies often lack durability or specificity or broad immunosuppression.
The recent appointment of Jolie M. Siegel as Executive Vice President, General Counsel brings over two decades of specialized biotechnology legal and transactional experience, including guiding C4 Therapeutics through significant growth and Neon Therapeutics through its acquisition by BioNTech, indicating strengthened capacity to navigate complex intellectual property landscapes, secure favorable partnership or licensing deals, and manage regulatory and compliance risks as the company advances its pipeline, which is critical for a clinical-stage biotech preparing for potential inflection events such as Phase 2 data readouts or strategic transactions that could unlock non-dilutive funding or validate platform value.
The addition of H. Martin Seidel, Ph.D., to the Scientific Advisory Board provides deep expertise in drug discovery, translational science, and portfolio strategy from leadership roles at Novartis and IFM Therapeutics, where he oversaw multiple successful portfolio company exits, suggesting enhanced ability to prioritize high-potential targets, optimize clinical development paths, and make informed go/no-go decisions that increase the probability of clinical success and efficient capital allocation, directly addressing a key investor concern in early-stage biotech: whether the science can reliably translate into viable clinical candidates.
Odyssey’s focus on developing medicines designed to precisely target disease pathology—rather than broad immune suppression—aligns with a growing structural shift in immunology toward precision medicine, where next-generation therapies aim for deep and durable remission with improved safety profiles, and if successful, this approach could differentiate the company’s pipeline in crowded markets like inflammatory bowel disease or rheumatoid arthritis, where current standards of care often lose efficacy over time or carry significant side effects, creating a potential long-term commercial advantage if clinical validation follows.
The company’s emphasis on internal discovery and development, coupled with a comprehensive suite of tools to efficiently advance product candidates, indicates a scalable and capital-efficient R&D model that reduces reliance on external innovation and lowers attrition risk through better target validation, which, if sustained, could lead to a higher hit rate in clinical development compared to peers and support a durable pipeline capable of generating multiple near-term catalysts, a factor often underestimated by the market when valuing early-stage immunology companies solely on near-term cash burn.

▼ Bear case

Odyssey Therapeutics remains a clinical-stage biopharmaceutical company with no approved products and no near-term revenue, meaning its valuation is entirely dependent on future clinical success, and despite achieving multiple preclinical milestones quickly, the transition from early clinical data to pivotal trial success in complex autoimmune indications like Crohn’s disease or ulcerative colitis remains highly uncertain, with historical failure rates in Phase 2 and 3 exceeding 70% for many immunology targets due to lack of efficacy or safety concerns, a risk the market may be underpricing given the company’s limited clinical track record beyond early-phase signals.
While the appointments of Jolie M. Siegel and H. Martin Seidel strengthen legal and scientific governance, neither addresses the core existential risk for Odyssey: the ability to demonstrate clinically meaningful differentiation in crowded therapeutic areas where established players like AbbVie, Johnson & Johnson, and emerging biotechs have deep pipelines and significant resources, and without clear early evidence of superior efficacy, durability, or safety in human data, the company’s platform advantage remains unproven, leaving it vulnerable to being perceived as another me-too player in a sector where differentiation is hard to achieve and even harder to sustain.
The company’s reliance on internal discovery, while potentially efficient, also concentrates risk in a single proprietary approach; if its target selection or drug design methodology fails to yield candidates with optimal pharmacological properties, there is no visible evidence of external validation or partnership interest to date that would suggest broader confidence in the platform, increasing the chance of prolonged preclinical delays or clinical attrition that could erode investor confidence and necessitate dilutive financing at unfavorable terms.
Autoimmune and inflammatory disease markets, while large, are becoming increasingly crowded with biologics, small molecules, and emerging modalities like cell therapies, and payers are demanding clear evidence of superior outcomes or cost-effectiveness, meaning Odyssey will need not only statistical significance but clinically meaningful differentiation to secure reimbursement and market share, a bar that is rising and may be difficult to meet without breakthrough data, especially if competitors continue to innovate on mechanisms of action or delivery systems.
The absence of any recent earnings call transcript or detailed clinical data update in the provided information limits transparency into the company’s current progress, cash runway, or specific timelines for upcoming milestones, creating uncertainty about near-term catalysts and increasing the risk that investors are pricing in optimistic scenarios without sufficient visibility into execution risks, a common issue in early-stage biotech where news flow is sparse and valuations can become disconnected from clinical reality.

Odyssey Therapeutics remains a clinical-stage biopharmaceutical company with no approved products and no near-term revenue, meaning its valuation is entirely dependent on future clinical success, and despite achieving multiple preclinical milestones quickly, the transition from early clinical data to pivotal trial success in complex autoimmune indications like Crohn’s disease or ulcerative colitis remains highly uncertain, with historical failure rates in Phase 2 and 3 exceeding 70% for many immunology targets due to lack of efficacy or safety concerns, a risk the market may be underpricing given the company’s limited clinical track record beyond early-phase signals.
While the appointments of Jolie M. Siegel and H. Martin Seidel strengthen legal and scientific governance, neither addresses the core existential risk for Odyssey: the ability to demonstrate clinically meaningful differentiation in crowded therapeutic areas where established players like AbbVie, Johnson & Johnson, and emerging biotechs have deep pipelines and significant resources, and without clear early evidence of superior efficacy, durability, or safety in human data, the company’s platform advantage remains unproven, leaving it vulnerable to being perceived as another me-too player in a sector where differentiation is hard to achieve and even harder to sustain.
The company’s reliance on internal discovery, while potentially efficient, also concentrates risk in a single proprietary approach; if its target selection or drug design methodology fails to yield candidates with optimal pharmacological properties, there is no visible evidence of external validation or partnership interest to date that would suggest broader confidence in the platform, increasing the chance of prolonged preclinical delays or clinical attrition that could erode investor confidence and necessitate dilutive financing at unfavorable terms.
Autoimmune and inflammatory disease markets, while large, are becoming increasingly crowded with biologics, small molecules, and emerging modalities like cell therapies, and payers are demanding clear evidence of superior outcomes or cost-effectiveness, meaning Odyssey will need not only statistical significance but clinically meaningful differentiation to secure reimbursement and market share, a bar that is rising and may be difficult to meet without breakthrough data, especially if competitors continue to innovate on mechanisms of action or delivery systems.
The absence of any recent earnings call transcript or detailed clinical data update in the provided information limits transparency into the company’s current progress, cash runway, or specific timelines for upcoming milestones, creating uncertainty about near-term catalysts and increasing the risk that investors are pricing in optimistic scenarios without sufficient visibility into execution risks, a common issue in early-stage biotech where news flow is sparse and valuations can become disconnected from clinical reality.

Peer group

Peer Comparison

Companies in the Pharmaceuticals

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,141.15 Bn	42.72	14.32	54.91 Bn
2	JNJ	Johnson & Johnson	641.74 Bn	39.87	6.46	44.65 Bn
3	ABBV	AbbVie Inc.	507.44 Bn	80.42	7.88	70.82 Bn
4	MRK	Merck & Co., Inc.	346.73 Bn	109.27	5.21	53.91 Bn
5	NVS	Novartis Ag	298.40 Bn	18.92	5.45	9.59 Bn
6	AZN	Astrazeneca Plc	266.58 Bn	25.52	4.54	32.35 Bn
7	AMGN	Amgen Inc	240.04 Bn	27.46	6.30	57.30 Bn
8	GILD	Gilead Sciences, Inc.	197.28 Bn	-60.89	6.48	26.25 Bn

Odyssey Therapeutics ODTX

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password